Emcure Pharmaceuticals Limited has issued a clarification to BSE Limited regarding the recent significant increase in its share volume, stating that the movement is entirely market-driven and outside the company's control.

BSE Query and Company Response

The clarification came in response to BSE's email dated March 10, 2026, which sought explanation for the notable increase in trading volume of the company's shares. The exchange's surveillance department had flagged the unusual activity under reference number L/SURV/ONL/PV/APJ/2025-2026/961.

Regulatory Compliance Statement

Emcure Pharmaceuticals emphasized its commitment to regulatory compliance, confirming that there are no undisclosed events or information that require disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company assured that it remains aware of its disclosure obligations and has consistently ensured timely disclosure of all material events and information.

Key Points from the Clarification

The pharmaceutical company highlighted several important aspects in its response:

• The price and volume increase is market-driven and beyond company control
• No material events currently require disclosure under SEBI Listing Regulations
• The company maintains strict adherence to disclosure timelines
• Commitment to continue transparent reporting of future material events

Company Leadership

The clarification was signed by Amruta Yangalwar, Company Secretary and Compliance Officer (Membership Number: A25687), who digitally authenticated the document on March 10, 2026. The response demonstrates the company's proactive approach to addressing regulatory queries and maintaining transparency with stock exchanges and investors.

Emcure Pharmaceuticals announced the appointment of Mr. C S Muralidharan as Additional Director (Non-Executive and Independent) following its board meeting held on March 09, 2026. The board meeting commenced at 12:15 p.m. (IST) and concluded at 12:40 p.m. (IST), addressing significant governance matters in compliance with SEBI regulations.

Board Approves Independent Director Appointment

Based on the recommendation of the Nomination and Remuneration Committee, the board approved the appointment of Mr. C S Muralidharan (DIN: 00014740) as an Additional Director (Non-Executive and Independent) with effect from April 01, 2026. He will serve as an Independent Director for an initial term of three consecutive years, subject to approval by the company's members.

Director Profile and Experience

Mr. C S Muralidharan brings extensive corporate experience spanning 40 years across hydrocarbon and pharmaceutical sectors. He has held various board and senior leadership positions across multiple entities in India, Asia, and Europe. His expertise includes strategic partnerships, M&A transactions, enterprise risk management, capital restructuring, enterprise transformation, and ESG initiatives.

His professional background includes roles with prominent organizations including Indian Oil Corporation Limited, Ranbaxy Group, Lupin Limited, Matrix Laboratories Limited, Watson Group, and Sun Pharmaceutical Industries Limited, where he served as Group Chief Financial Officer. In his last role, he was responsible for global finance, strategy, M&A, investor relations, governance, and compliance.

Qualifications and Educational Background

Mr. Muralidharan holds qualifications as a Cost & Management Accountant with a Master's degree in Commerce. He has completed the Executive Program in General Management from Booth School of Business, University of Chicago, further strengthening his leadership credentials.

Regulatory Compliance and Independence

The company confirmed that Mr. Muralidharan is not debarred from holding directorship by any SEBI order and complies with BSE Circular No. LIST/COMP/14/2018-19 dated June 20, 2018, and NSE Circular No. NSE/CML/2018/02 dated June 20, 2018. The appointment was made pursuant to Regulation 30 of the SEBI Listing Regulations and reference HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026.

The appointment ensures independence in his role as he is not related to any existing Directors or Key Managerial Personnel of the company, maintaining corporate governance standards.